在人类肿瘤中表达的内源性逆转录病毒不能用作抗肿瘤疫苗的靶标。

IF 4.5 2区医学 Q1 ONCOLOGY

Translational Oncology Pub Date : 2021-01-01 Epub Date: 2020-11-19 DOI:10.1016/j.tranon.2020.100941

Joachim Denner

引用次数: 3

摘要

许多肿瘤细胞在其表面表达内源性逆转录病毒(erv)蛋白，有人建议将这些逆转录病毒抗原作为抗肿瘤疫苗的靶点。然而，到目前为止，还没有令人信服的数据表明这种策略有效，相反，有考虑表明，这种策略如果应用可能是有害的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Endogenous retroviruses expressed in human tumours cannot be used as targets for anti-tumour vaccines.

Many tumour cells express on their surface proteins of endogenous retroviruses (ERVs) and there are suggestions to use these retroviral antigens as target for anti-tumour vaccines. However, until now there is no convincing data showing that this strategy works, in contrast, there are considerations suggesting that this strategy may be harmful if applied.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Translational Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

7.20

自引率

2.00%

发文量

314

审稿时长

6-12 weeks

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.